If you are researching Botox for horizontal forehead lines, you will almost certainly encounter med spa menus, online price calculators, and social media posts offering "10 to 30 units of forehead Botox" as a standalone, 15-minute lunchtime treatment.
The clinical and regulatory reality is fundamentally different: For BOTOX Cosmetic (and Xeomin), horizontal forehead lines are an FDA-approved indication only when treated in conjunction with glabellar lines (the "11s") at the same visit—at a labeled total of 40 Units (20 Units in the frontalis plus 20 Units in the glabella).
Treating the forehead in isolation without treating the glabella is not the labeled FDA protocol for either approved toxin. Furthermore, out of the six botulinum toxin type A products currently approved for aesthetic use in the United States, only two (Botox Cosmetic and Xeomin) carry FDA approval for horizontal forehead lines. The remaining four—Jeuveau, Dysport, Daxxify, and Letybo—are FDA-approved exclusively for glabellar lines in the upper face.
[US Aesthetic Neurotoxin Upper-Face Label Map]
Product (BLA / Applicant) Forehead Lines (HFL) Frown Lines (GL) Crow's Feet (LCL)
───────────────────────── ──────────────────── ──────────────── ─────────────────
BOTOX Cosmetic (BLA 103000) ON-LABEL (S-5303)* ON-LABEL (S-5000) ON-LABEL (S-5251)
XEOMIN (BLA 125360) ON-LABEL (SUPPL 99)* ON-LABEL (SUPPL 7) ON-LABEL (SUPPL 99)*
JEUVEAU (BLA 761085) Off-Label ON-LABEL (Orig) Off-Label
DYSPORT (BLA 125274) Off-Label ON-LABEL (Orig) Off-Label
DAXXIFY (BLA 761127) Off-Label ON-LABEL (Orig)** Off-Label
LETYBO (BLA 761225) Off-Label ON-LABEL (Orig) Off-Label
*Labeled only when treated in conjunction with glabellar lines (20 U + 20 U = 40 U).
**Daxxify is also approved for cervical dystonia (SUPPL 2); its 40 U label dose is for glabella only.
Understanding the anatomical mechanics of the frontalis muscle, the clinical trial safety data, and the strict rules governing on-label upper-face neurotoxin dosing is critical before scheduling an injection appointment.
Direct Answer: Can I Treat Forehead Lines With Botox and Skip the 11s?
Under the official US Prescribing Information (PI) for BOTOX Cosmetic (DailyMed setid 485d9b71-6881-42c5-a620-a4360c7192ab, October 21, 2024 PI bundle), no.
The FDA-approved dosage and administration instructions state explicitly:
"Treat forehead lines in conjunction with glabellar lines to minimize the potential for brow ptosis."
The Labeled Dosing Math
- Frontalis (Horizontal Forehead Lines): 20 Units total, reconstituted in 0.5 mL of sterile, preservative-free 0.9% sodium chloride, distributed evenly across 5 injection sites at 4 Units (0.1 mL) per site.
- Glabella (Frown Lines / "11s"): 20 Units total, reconstituted in 0.5 mL, administered into 5 injection sites at 4 Units (0.1 mL) per site (one into the procerus, two into each corrugator supercilii).
- Combined Visit Total: 40 Units (1.0 mL total volume).
- Full Upper-Face Treatment (Forehead + Glabella + Crow's Feet): Adding lateral canthal lines (crow's feet, 24 Units: 3 sites of 4 Units per side) brings the total labeled upper-face dose to 64 Units.
[Labeled BOTOX Cosmetic Upper-Face Injection Map]
[ 4U ] [ 4U ] (Upper Frontalis Row)
[ 4U ] [ 4U ] [ 4U ] (Lower Frontalis Row)
───────────────────────────────────────── ≥ 2 cm above the eyebrow
\ || /
[ 4U ] [ 4U ] [ 4U ] (Corrugators & Procerus)
[ 4U ] [ 4U ] (Glabellar 20 Units)
(•) (•) (Pupillary Line)
• Frontalis: 5 sites × 4 Units = 20 Units (Must treat with Glabella)
• Glabella: 5 sites × 4 Units = 20 Units
• Total Forehead + Glabella Session: 40 Units (1.0 mL)
While an individual clinician may legally choose to inject fewer units or treat the frontalis off-label in isolation based on clinical judgment, a "forehead-only" 10-to-20 unit injection is not the FDA-approved protocol. Clinics that quote 20 units as a standalone forehead visit are selling an off-label pattern that increases the risk of brow heaviness and brow descent.
To explore how the glabella is treated when injected on its own, see our guide on Botox for frown lines and the 11s. For lateral canthal line dosing, review Botox for crow's feet.
Which US Toxins Are FDA-Approved for Forehead Lines?
A widespread misconception among patients is that all FDA-approved "Botox alternatives" share the same approved indications across the face. In reality, the FDA evaluates each neurotoxin Biologics License Application (BLA) and efficacy supplement individually.
In FDA's Drugs@FDA data files (16 August 2026 snapshot: 29,270 applications, 51,652 products, 193,399 submissions), the six aesthetic botulinum toxin type A products display distinct regulatory profiles:
[FDA Regulatory Milestones for US Aesthetic Toxins]
Brand (BLA #) Indication Expansion Milestone Approval Date Class / Code
────────────────── ─────────────────────────────────── ─────────────── ────────────
BOTOX Cosmetic S-5000: Glabellar Lines (Orig Cosm) 2002-04-12 Efficacy (2)
(BLA 103000) S-5251: Lateral Canthal Lines 2013-01-18 Efficacy (2)
S-5303: Horizontal Forehead Lines 2017-10-02 Efficacy (2)
S-5331: Platysma Prominence (Neck) 2024-10-18 Efficacy (2)
────────────────── ─────────────────────────────────── ─────────────── ────────────
XEOMIN SUPPL 7: Glabellar Lines (Cosmetic) 2011-07-20 Efficacy (2)
(BLA 125360) SUPPL 99: HFL + LCL (upper face)* 2024-07-05 Efficacy (2)
────────────────── ─────────────────────────────────── ─────────────── ────────────
JEUVEAU (761085) ORIG-1: Glabellar Lines Only 2019-02-01 Original (1)
DAXXIFY (761127) ORIG-1: Glabellar Lines (40 Units) 2022-09-07 Original (1)
SUPPL 2: Cervical Dystonia 2023-08-11 Efficacy (2)
LETYBO (761225) ORIG-1: Glabellar Lines Only 2024-02-29 Original (1)
DYSPORT (125274) ORIG-1: Glabellar Lines (50 Units) 2009-04-29 Original (1)
*Merz announced simultaneous upper-face expansion on July 23, 2024; Drugs@FDA submission date is July 5, 2024.
1. BOTOX Cosmetic (onabotulinumtoxinA) — Allergan / AbbVie
The FDA approved BLA 103000/S-5303 on October 2, 2017 for the temporary improvement in the appearance of moderate to severe horizontal forehead lines associated with frontalis muscle activity. Forehead lines became Botox's third aesthetic indication, following glabellar lines in 2002 (S-5000) and crow's feet in 2013 (S-5251). In October 2024, Botox gained its fourth facial/neck aesthetic indication for platysma bands (S-5331; see Botox for platysma bands).
2. XEOMIN (incobotulinumtoxinA) — Merz Aesthetics
Xeomin (BLA 125360) is the only other US neurotoxin with on-label forehead approval. Cosmetic glabellar lines were added as SUPPL 7 (Drugs@FDA date July 20, 2011); the original 2010 BLA was cervical dystonia and blepharospasm, not a forehead indication. DailyMed SPL (setid 3f35d6e0-3450-4abc-a0da-cc7b277e7c6e) specifies that horizontal forehead lines must be treated in conjunction with glabellar lines (20 Units frontalis + 20 Units glabella = 40 Units maximum for these two areas, or 64 Units if crow's feet are included). In Drugs@FDA, the upper-face efficacy supplement that added both horizontal forehead lines and lateral canthal lines is SUPPL 99, SubmissionStatusDate July 5, 2024 (Merz issued a press release on July 23, 2024). There is no 2018 crow's-feet efficacy supplement for Xeomin; that date does not appear among BLA 125360 submissions. For a direct comparison between the two on-label options, see our detailed guide on Xeomin vs. Botox.
3. Jeuveau, Dysport, Daxxify, and Letybo
- Jeuveau (prabotulinumtoxinA-xvfs): DailyMed SPL explicitly notes it is not approved for indications other than glabellar lines. See Jeuveau vs. Botox.
- Daxxify (daxibotulinumtoxinA-lanm): Labeled for glabellar lines (40 Units) and cervical dystonia. Its 40-unit label dose is for the frown lines, not the forehead. See how long Botox and neurotoxins last.
- Dysport (abobotulinumtoxinA): Labeled for glabellar lines (50 Units) and therapeutic indications; no US forehead indication.
- Letybo (letibotulinumtoxinA-wlbg): Approved in February 2024 for glabellar lines only. For a broader overview of the six products, see our comparison of types of FDA-approved neurotoxins.
Injecting Jeuveau, Dysport, Daxxify, or Letybo into the forehead is legal under standard medical off-label practice, but there are no FDA-reviewed PI unit maps, clinical trial tables, or approved safety claims for frontalis treatment with those four brands.
The Biomechanics of the Frontalis: Why Brow Ptosis and "Spock Brow" Happen
To understand why the conjunction rule exists and why forehead injections require precision, one must examine the muscular anatomy of the upper face.
[Upper-Face Muscular Force Balance]
Frontalis Muscle (ONLY Brow Elevator)
▲ ▲ ▲ ▲ ▲
[ Pulls Brow UPWARD ]
─────────────────────────
[ Pulls Brow DOWNWARD ]
▼ ▼ ▼ ▼ ▼
Depressors: Corrugators, Procerus, Depressor Supercilii,
and Lateral Orbicularis Oculi
1. The Frontalis Is the Sole Brow Elevator
The upper face operates on an antagonistic muscular balance:
- The Elevator: The frontalis muscle is the only muscle in the human face that lifts the eyebrows upward.
- The Depressors: The procerus, corrugator supercilii, depressor supercilii, and orbicularis oculi pull the brows downward and medially (inward).
When an injector administers 20 Units of Botox into the frontalis, the frontalis muscle relaxes, smoothing the horizontal skin creases above it. However, because the elevator is weakened, the downward-pulling depressors unopposedly drag the eyebrow down.
If the glabella (the depressor complex) is not treated at the exact same time, the patient experiences a heavy, flattened brow—a condition known clinically as brow ptosis. By treating the glabella (20 Units) simultaneously, the downward pull of the depressors is eliminated, maintaining neutral brow positioning.
2. Anatomical Injection Boundaries
To prevent medication from diffusing into the orbital septum and levator palpebrae superioris (which causes eyelid ptosis), the BOTOX Cosmetic PI mandates strict anatomical margins:
- Height Margin: The PI locates the lower frontalis row at least 2 centimeters above the eyebrow, midway between the superior margin of frontalis activity and the eyebrow. That is a labeled placement rule, not a license to drop the row onto the orbital rim.
- Lateral Margin: The lateral injection sites must be placed 0.5 to 1.5 centimeters medial to the temporal fusion line (the palpable ridge along the lateral forehead where the frontalis fascia transitions into the temporalis fascia).
[Frontalis Placement Geometry]
Hairline
┌─────────────────────────────────────────────────────────┐
│ │
│ [ • 4U ] [ • 4U ] │ Upper Row
│ │
│ [ • 4U ] [ • 4U ] [ • 4U ] │ Lower Row
│ │
├─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ┤ Safety Line (≥ 2 cm)
│ │
│ Temporal Temporal │
│ Fusion Line Fusion Line │
│ | | │
│ ▼ ▼ │
│ ( Brow ) ( Brow ) │
└─────────────────────────────────────────────────────────┘
3. What Causes a "Spock Brow" (Mephisto Sign)?
A "Spock brow"—where the lateral tail of the eyebrow arches unnaturally high while the central brow remains frozen—is not an adverse reaction to the toxin itself. It is a placement and distribution error:
- Mechanism: The central frontalis fibers are completely paralyzed by central injections, but the lateral frontalis fibers (lateral to the temporal fusion line) remain un-injected and active.
- Result: When the patient attempts to elevate the forehead, the frozen central muscle cannot move, but the hyperactive lateral frontalis fibers pull the brow tail sharply upward toward the hairline.
- Prevention & Correction: Injectors typically add a small amount of toxin into the still-active lateral frontalis. That touch-up is a common off-label placement adjustment, not an FDA-labeled dose or a numbered protocol.
What Did the FDA Forehead Clinical Trials Measure?
During the clinical development program for BLA 103000/S-5303, Allergan evaluated BOTOX Cosmetic in randomized, double-blind, placebo-controlled trials in subjects with moderate to severe horizontal forehead lines.
In the safety population evaluating 20 Units in the frontalis in conjunction with 20 Units in the glabella (N=665 treated subjects) compared against placebo (N=315 subjects), the 2024 PI forehead-line adverse-reaction table (captioned Table 6; the surrounding text also refers to it as Table 7) reported:
[BOTOX Cosmetic Forehead-Line Adverse Reactions, 2024 PI]
Adverse Reaction (MedDRA Term) BOTOX 20U + 20U (N=665) Placebo (N=315)
────────────────────────────── ─────────────────────── ───────────────
Headache 58 (9%) 17 (5%)
Eyelid Ptosis (Drooping Eyelid) 12 (2%) 1 (0%)
Brow Ptosis (Drooping Eyebrow) 13 (2%) 0 (0%)
Skin Tightness 10 (2%) 0 (0%)
Key Clinical Trial Insights
- Low Eyelid and Brow Ptosis Rates Under Labeled Protocol: With the labeled 20-plus-20 map and a ≥2 cm margin above the eyebrow, eyelid ptosis was 12/665 (2%) vs 1/315 (0%) and brow ptosis 13/665 (2%) vs 0%.
- Headache as the Leading Event: Headache occurred in 9% of treated subjects vs. 5% of placebo subjects.
- Primary Efficacy Was a Composite ≥2-Grade Improvement, Not an 80% "None or Mild" Rate: The forehead-line co-primary was a composite investigator-plus-subject ≥2-grade improvement in forehead-line severity at maximum eyebrow elevation at Day 30. Study 1: 61% (N=290) vs 0% placebo (N=101). Study 2: 46% with 40 Units (N=318) and 53% with 64 Units including crow's feet (N=313) vs 1% placebo (N=156). The often-quoted ~80% "none or mild at Day 30" figure in the same PI is from the glabellar-line investigator table, not the forehead primary. A key secondary ("none or mild" forehead lines on investigator ratings) is shown as a figure, not as a single 80% number for both raters.
Who Should Skip Forehead Botox? (The "Brow Crane" Problem)
Forehead Botox is not suitable for every patient with horizontal lines. In some anatomical presentations, horizontal forehead lines are not an aesthetic flaw—they are a vital physiological adaptation.
[The Compensatory Frontalis Mechanism]
Patient Anatomy Physiological Response
─────────────── ──────────────────────
Dermatochalasis (Excess Upper Lid) Patient chronically contracts frontalis
or Pre-existing Brow Ptosis ───► to lift eyebrow and hoist eyelid skin
out of the visual field.
Action: Inject 20U Forehead Botox
─────────────────────────────────
Result: Frontalis paralyzed ───► Brow descends ───► Eyelid skin folds over lashes
(Pseudoptosis / Visual Obscuration)
1. Compensated Brow Ptosis and Dermatochalasis
Many individuals in their 40s, 50s, and 60s develop excess, lax upper eyelid skin (dermatochalasis) or true descending brow tissue (brow ptosis).
To keep this heavy skin from folding over the eyelashes and obstructing the superior visual field, the brain unconsciously fires the frontalis muscle 24 hours a day. This chronic contraction lifts the brow like a construction crane—and creates deep horizontal forehead creases.
If an injector paralyzes the frontalis in such a patient:
- The "crane" is deactivated.
- The eyebrows drop heavily over the orbital rim.
- The patient feels immense ocular pressure and appears tired, angry, or hooded.
For patients with this anatomy, the appropriate solution is not neurotoxin, but an upper blepharoplasty or surgical brow lift. Review our guide on hooded eyes, dermatochalasis, and brow ptosis and surgical brow lift recovery and techniques.
2. Deep Static Etched-in Rhytids
Dynamic lines appear only when moving; static lines remain visible when the face is completely at rest. If horizontal forehead lines have been present for decades, the dermal collagen has fractured. Freezing the frontalis stops the line from worsening, but it will not erase the static crease. Combining light neuromodulator dosing with topical retinoids, chemical peels, or fractional resurfacing is necessary for dermal remodeling.
3. "Baby Botox" and Natural Movement Requests
Patients seeking subtle movement often ask for "baby Botox" (lower-than-label frontalis dosing). That is an off-label technique, not an FDA-approved dosing tier. Read our analysis of Baby Botox vs. Regular Botox and techniques for natural-looking Botox.
Cost Comparison: 20-Unit Forehead Quote vs. 40-Unit Labeled Visit
When med spas advertise forehead Botox pricing, they frequently quote 10 to 20 forehead-only units as a standalone visit. That is not the labeled BOTOX Cosmetic or Xeomin map. Because on-label forehead treatment requires 20 Units in the frontalis plus 20 Units in the glabella, the visit you are actually buying is a 40-Unit upper-face map (or 64 Units if labeled crow's feet are added). Dollar math belongs on Botox price per unit vs. price per area; this page owns why the unit count is 40, not 20.
Frequently Asked Questions
How many units of Botox for the forehead?
Under the official FDA label for BOTOX Cosmetic and Xeomin, the approved dose for horizontal forehead lines is 20 Units in the frontalis, administered only in conjunction with 20 Units in the glabella, for a total visit dose of 40 Units. Many injectors adjust doses off-label (using 10 to 15 Units in the forehead) depending on patient muscle mass and brow height.
Is 20 units of Botox enough for forehead lines?
The labeled forehead dose is 20 Units across 5 sites (4 Units per site), always paired with 20 Units in the frown lines. In the forehead-line trials, the Day 30 composite ≥2-grade improvement rate was 61% vs 0% placebo in Study 1, not an 80% "none or mild" rate. The 80% Day 30 none-or-mild figure in the same PI is from the glabellar-line studies.
Can I get forehead Botox without treating my 11s?
Technically an injector can inject only the frontalis off-label, but it is contrary to FDA labeling. Paralyzing the frontalis (the only brow elevator) while leaving the glabellar depressors active significantly increases the risk of heavy, descending eyebrows (brow ptosis).
Which is better for forehead lines, Botox or Xeomin?
Both BOTOX Cosmetic and Xeomin are FDA-approved for horizontal forehead lines using the same labeled 20 Units frontalis + 20 Units glabella = 40 Units map (and 64 Units with crow's feet). Xeomin is manufactured without accessory proteins; Botox is supplied as a 900 kDa complex. Those formulation differences are not a ranked "better for forehead" result, and this page is not a head-to-head duration trial. See Xeomin vs. Botox and how long Botox lasts.
What is a Spock brow after Botox?
A "Spock brow" (or Mephisto sign) occurs when the central frontalis is paralyzed but the lateral edges of the muscle are left untreated. The active lateral fibers pull the outer tail of the eyebrow unnaturally high. It is a placement pattern, not a labeled MedDRA adverse reaction, and it is usually addressed by treating the still-active lateral frontalis — an off-label touch-up, not a numbered FDA dose.
Is Dysport or Jeuveau FDA-approved for the forehead?
No. In the United States, Dysport, Jeuveau, Daxxify, and Letybo are FDA-approved exclusively for glabellar lines (frown lines / 11s) in the facial aesthetic arena. Using them in the forehead is off-label.
Sources
- DailyMed — BOTOX Cosmetic (onabotulinumtoxinA) Prescribing Information SPL (October 21, 2024 PI Bundle): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485d9b71-6881-42c5-a620-a4360c7192ab
- FDA CDRH/CDER — BLA 103000/S-5303 Efficacy Supplement Approval Letter (Forehead Lines Indication, October 2, 2017): https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/103000Orig1s5303ltr.pdf
- FDA CDER — BOTOX Cosmetic Full Prescribing Information PDF (2024 Label Bundle 103000s5316s5319s5323s5326s5331lbl): https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103000s5316s5319s5323s5326s5331lbl.pdf
- DailyMed — XEOMIN (incobotulinumtoxinA) Prescribing Information SPL (Upper Facial Lines Expansion): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f35d6e0-3450-4abc-a0da-cc7b277e7c6e
- DailyMed — JEUVEAU (prabotulinumtoxinA-xvfs) Prescribing Information SPL: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17a914c1-e54b-4b50-965d-b0fd9111bba4
- DailyMed — DAXXIFY (daxibotulinumtoxinA-lanm) Prescribing Information SPL: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3aaa6e14-a3f7-4fb2-b9f9-d3a9c3ae1f74
- DailyMed — LETYBO (letibotulinumtoxinA-wlbg) Prescribing Information SPL: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=910e5d0e-4d0b-4de8-8e2d-97879a044181
- DailyMed — DYSPORT (abobotulinumtoxinA) Prescribing Information SPL: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71313a04-1349-4c26-b840-a39e4a3ddaed
- FDA CDER — Drugs@FDA Data Files and Application Database (Snapshot August 2026): https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files
- American Academy of Dermatology (AAD) — Botulinum Toxin Overview & Patient Safety: https://www.aad.org/public/cosmetic/wrinkles/botulinum-toxin-overview
- American Society for Dermatologic Surgery (ASDS) — Neuromodulators for Facial Rejuvenation: https://www.asds.net/skin-experts/skin-treatments/neuromodulators
